Washington-based AI-powered synthetic biology company AbSci and Spain-based AI drug discovery company Almirall have collaborated to develop and commercialize AI-designed dermatological therapies. Absci will receive up to USD 650 million in upfront fees, R&D, and post-approval milestone payments of the two programs under the terms of the agreement.
The partnership will combine Absci's AI technology and Almirall’s expertise in dermatology to generate medicines for patients. Absci will create and commercialize potential drug candidates for two dermatological targets leveraging its de novo GenAI platform. This strategic agreement is Almirall's first venture into AI therapeutic collaborations and comes after Absci's announcement of its AI's capability to design, validate, and produce therapeutic antibodies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.